Company Plans to Complete Series C Financing in Fourth Quarter of 2019, Followed by Initial Public Offering for 2020   SAN DIEGO, Sept. 5, 2019 /PRNewswire/ — Precision IBD, Inc., a biopharmaceutical company focused on the discovery and development of a broad portfolio of precision therapeutics and